Aspire Biopharma Holdings, Inc. will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026 at 2:00 pm ET. The event is a live, interactive online forum where investors and industry professionals can submit questions to management in real time, with one-on-one meetings available on June 24th and 25th. A replay of the webcast will be available after the conference. Aspire Biopharma highlighted its lead drug candidate, a high-dose aspirin prescription product that demonstrated dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in a trial, along with its new caffeine product BUZZ BOMB which generated commercial revenue in 2025 and launched a new e-commerce website, packaging, and product in January 2026. The company also noted a proposed acquisition of Dura Driver Control Systems, a global automotive supplier with over $200 million in 2025 unaudited revenue, expected to close in the third quarter.
Aspire BioPharma, Inc.Company presenting at investor forum and highlighting acquisition of Dura Driver Control Systems with $200M revenue, which is a financial/valuation event.